|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0625 - 0.0700|
|52 Week Range||0.0100 - 0.2800|
|Beta (3Y Monthly)||4.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Saturday, Dec. 15 is the last day most Americans can sign up for an Obamacare health plan if they want coverage at the first of the year.
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 27) Aptinyx Inc (NASDAQ: APTX ) Cardiovascular Systems Inc (NASDAQ: ...
Today, Anthera Pharmaceuticals (ANTH) registered a stock price decline of ~53% on news that the stock will be suspended from trading on the NASDAQ Capital Market at the start of business tomorrow. Following the delisting, Anthera Pharmaceuticals’ securities will be listed on the OTC Market. If the company requires its stock to trade on another trading platform, it may take the necessary steps.